Abstract
Tumor-associated macrophages (TAMs) are M2 phenotype dominant and promote tumor growth and metastasis. The new cancer treatment strategy includes TAM targeting and is aimed primarily at reprogramming TAMs toward the M1 phenotype or reducing the number and activity of M2 macrophages. Several marine invertebrate-derived drugs, combining efficacy and a low level of side effects, were approved for use in the cancer therapy. The mechanisms of action of some of them include TAM targeting. The review includes data showing immunomodulatory properties of these already approved anticancer drugs and drug candidates in clinical development which additionally incorporate data from screening studies of new substances from marine invertebrates. Based on screening data, the most promising marine compounds for cancer immunotherapy are supposed.
Keywords: Marine invertebrate-derived compounds, tumor-associated macrophages, macrophage reprogramming, cytokines, NO, anticancer drugs, cancer immunotherapy.
Current Pharmaceutical Design
Title:Tumor-Associated Macrophages as Potential Targets for Anti-Cancer Activity of Marine Invertebrate-Derived Compounds
Volume: 27 Issue: 28
Author(s): Lyudmila S. Dolmatova*Igor Y. Dolmatov
Affiliation:
- Laboratory of Biochemistry, V.I. Il`ichev Pacific Oceanological Institute, Far Eastern Branch, Russian Academy of Sciences, Vladivostok,Russian Federation
Keywords: Marine invertebrate-derived compounds, tumor-associated macrophages, macrophage reprogramming, cytokines, NO, anticancer drugs, cancer immunotherapy.
Abstract: Tumor-associated macrophages (TAMs) are M2 phenotype dominant and promote tumor growth and metastasis. The new cancer treatment strategy includes TAM targeting and is aimed primarily at reprogramming TAMs toward the M1 phenotype or reducing the number and activity of M2 macrophages. Several marine invertebrate-derived drugs, combining efficacy and a low level of side effects, were approved for use in the cancer therapy. The mechanisms of action of some of them include TAM targeting. The review includes data showing immunomodulatory properties of these already approved anticancer drugs and drug candidates in clinical development which additionally incorporate data from screening studies of new substances from marine invertebrates. Based on screening data, the most promising marine compounds for cancer immunotherapy are supposed.
Export Options
About this article
Cite this article as:
Dolmatova S. Lyudmila *, Dolmatov Y. Igor , Tumor-Associated Macrophages as Potential Targets for Anti-Cancer Activity of Marine Invertebrate-Derived Compounds, Current Pharmaceutical Design 2021; 27 (28) . https://dx.doi.org/10.2174/1381612827666210319125652
DOI https://dx.doi.org/10.2174/1381612827666210319125652 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology Managing Skin Malignancies- How Family Doctors, Plastic Surgeons, and Dermatologists Can Help
Current Cancer Therapy Reviews Development of Heparanase Inhibitors for Anti-Cancer Therapy
Current Medicinal Chemistry Advanced Platelet-Rich Fibrin Extract Treatment Promotes the Proliferation and Differentiation of Human Adipose-Derived Mesenchymal Stem Cells through Activation of Tryptophan Metabolism
Current Stem Cell Research & Therapy Multiple Means by Which Nitric Oxide can Antagonize Photodynamic Therapy
Current Medicinal Chemistry The In Silico Prediction of Human-Specific Metabolites from Hepatotoxic Drugs
Current Drug Discovery Technologies AKT Signaling in Regulating Angiogenesis
Current Cancer Drug Targets XMT-1001, A Novel Biodegradable Polyacetal Polymer Conjugate of Camptothecin in Clinical Development
Current Bioactive Compounds Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
Current Medicinal Chemistry Curcumin and its Formulations: Potential Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry HGF and RhoGTPases in Cancer Cell Motility
Current Signal Transduction Therapy The Pathogenic Role of Intestinal Flora in IBD and Colon Cancer
Current Drug Targets Relative In Vitro Potentials of Parthenolide to Induce Apoptosis and Cell Cycle Arrest in Skin Cancer Cells
Current Drug Discovery Technologies Nitric Oxide: State of the Art in Drug Design
Current Medicinal Chemistry Effect of Contrast-enhanced Contemporaneous <sup>18</sup>F-FDG PET/CT on Semi Quantification Uptake Value Using Third Party Viewing Workstation
Recent Patents on Medical Imaging Isoliquiritigenin (ISL) and its Formulations: Potential Antitumor Agents
Current Medicinal Chemistry LncRNA as a Therapeutic Target for Angiogenesis
Current Topics in Medicinal Chemistry Heparanase Patents: Dim Past and Bright Future
Recent Patents on Inflammation & Allergy Drug Discovery Meet Our Editorial Board Member
Current Medicinal Chemistry Recent Advances in the Design and Synthesis of c-Met Inhibitors as Anticancer Agents (2014-Present)
Current Medicinal Chemistry